medigraphic.com

2006, Number 2

<< Back Next >>

Arch Cardiol Mex 2006; 76 (2)

The possible clinical role of the cardiac pulmonary power in patients with primary pulmonary hypertension. Initial observations

Lupi HE, Sandoval ZJ, Chuquiure VE, Carrillo A

Language: Spanish
References: 44
Page: 140-150
PDF size: 179.16 Kb.


ABSTRACT

The heart is a muscular mechanical pump with an ability to generate both flow [cardiac output] and pressure in the systemic circulation as well in the pulmonary vascular bed. The product of flow output and systemic arterial pressure is the rate of useful work done, or cardiac power output [CP], therefore for the right ventricle and the pulmonary arterial vascular bed it will be: the product of flow output and mean pulmonary arterial pressure will be the rate of useful work done, or cardiac pulmonary power output [CPP]. Cardiac pulmonary pumping reserve capability can be defined as the maximal cardiac pulmonary power output [CPP] achieved by the right heart during maximal stimulation. Therefore, CPP reserve is the increase in power output as the cardiac performance is increased from the resting to the maximally stimulated state. Recently, several studies have shown that CP is a direct indicator of overall cardiac function, as well is an indicator of exercise capacity and a powerful predictor of prognosis for patients with severe heart failure and ischemic cardiogenic shock. On this basis: 1. we decided to investigate the possible previously mentioned roles of the CP and CPP in patients with different degrees of pulmonary arterial hypertension [n = 137], but mainly in those with primary pulmonary arterial hypertension [PPH]. PPH patients [n = 50], as well as those with Eisenmenger´s syndrome [n = 10] were found to have most abnormal resting CPP Indexes [I], [0.431 ± 0.171, 0.607 ± 0.124 watts/m2, respectively]. During exercise in PPH patients [n = 14], both CPI and CPPI reserves although they increase, were also found to be significantly diminished [CPI: from 0.546 ± 170 to 1,116 ± 0.275 watts/m2, p ‹ 0.05], [CPPI: from 0.373 ± 0.156 to 0.837 ± 0.226 watts/m2, p ‹ 0.05]. 2. We also found, significant differences in resting CPPI between PPH responders and no responders patients to hydralazine [0.273 ± 0.04, 0.507 ± 0.142 watts/m2, respectively, p ‹ 0.01]. During exercise and under the influence of hydralazine, CPPI “reserve” was significantly diminished in those patients considered as not responders [0.507 ± 0.142 to 0.723 ± 0.232 watts/m2, p = ns] when compared with responders to the vasodilator therapy [0.273 ± 0.04 to 0.903 ± 0.057 watts/m2, p ‹ 0.01]. On the basis of these initial findings on CPPI in PPH patients, we think that the values of this parameter should be investigated as an index for classifying the severity of this arterial vascular disease, for selecting patients as responders or not to vasodilator therapy, and in the future, to explore the possibility of is usefulness as a prognostic predictor index of mortality in a large population of patients with PPH.


REFERENCES

  1. CHATTERJEE K: Vasodilator therapy for heart failure. Ann Intern Med 1975; 83: 421-423.

  2. ZELIS R, FLAIM SF: Alterations in vasomotor tone in congestive heart failure. Prog Cardiovasc Dis 1982; 24: 437-459.

  3. MASON DT, ZELIS R, LONGHURST J, LEE G: Cardiocirculatory responses to muscular exercise in congestive heart failure. Prog Cardiovasc Dis 1977; 19: 475-489.

  4. TAN LB: Clinical and research implications of new concepts in the assessment of cardiac pumping performance in heart failure. Cardiovasc Research 1987; 21: 615-622.

  5. BENGE W, LITCHFIELD RL, MARCUS ML: Exercise Capacity in patients with severe left ventricular dysfunction. Circulation 1980; 60: 955-959.

  6. FRANCIOSA JA, PARK M, LEVINE TB: Lack of correlation between exercise capacity and indexes of resting left ventricular performance in heart failure. Am J Cardiol 1981; 47: 33-39.

  7. TAN LB: Cardiac pumping capability and prognosis in heart failure. Lancet 1987; ii: 1360-1363.

  8. BERGEL DH, CLARK C, SCHULTZ DL, TUNSTALL-PEDOE DS: The determination of the mechanical energy expenditure during ventricular pumping. J Physiol 1969; 204: 70-71P.

  9. PICARD MH, DAVIDOFF R, SLEEPER L, MENDES LA, THOMPSON CR, DZAVIK V, ET AL for the Shock Trial: Echocardiographic predictors of survival and response to early revascularization in cardiogenic shock. Circulation 2003; 107: 279-284.

  10. HASDAI D, HOLMES DR, CALIFF RM, THOMPSON TD, HOCHMAN JS, PFISTERER M, TOPOL EJ, GUSTO-I INVESTIGATORS: Cardiogenic shock complicating acute myocardial infarction: predictors of death. Am Heart J 1999; 138: 21-31.

  11. TAN LB, LITTLER WA: Measurement of cardiac reserve in cardiogenic shock: implications for prognosis and management. Br Heart J 1990; 64: 121-128.

  12. COTTER G, WILLIAMS SG, VERED Z, TAN LB: Role of cardiac power in heart failure. Curr Opin Cardiol 2003; 18: 215-222.

  13. COTTER G, MOSHKOVITZ Y, MILOVANOV O, SALAH A, BLATT A, KRAKOVER R, ET AL: Acute congestive heart failure: A novel approach to its pathogenesis and treatment. Eur J Heart Fail 2002; 4: 227-234.

  14. FINCKE R, HOCHMAN JS, LOWE AM, MENON V, SLATER JN, WEBB JG, ET AL, for the SHOCK Investigators: Cardiac power is the strongest hemodynamic correlate of mortality in cardiogenic shock: A report from the SHOCK Trial Registry. J Am Coll Cardiol 2004; 44: 340-348.

  15. LUPI HE, CHUQUIURE EV, CUÉLLAR B, ARIAS A, PACHECO HG, MARTÍNEZ SC: El poder cardíaco un instrumento del pasado, una herramienta moderna en la valoración clínica-terapéutica y pronóstica del Choque Cardiogénico por Síndrome Isquémico Coronario Agudo. Arch Cardiol Mex 2006; 76: en prensa.

  16. D´ALONZO GE, BARST RJ, AYRES SM, BERGOFSKY EH, BRUNDAGE BH, DETRE KM, ET AL: Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991; 115: 343-349.

  17. SANDOVAL J, BAURLE O, PALOMAR A, GÓMEZ A, MARTÍNEZ-GUERRA ML, BELTRÁN M, ET AL: Survival in primary pulmonary hypertension: validation of a prognostic equation. Circulation 1994; 89: 1733-1744.

  18. SIBON O, HUMBERT M, NUNES H, PARENT F, GARCÍA G, HERVÉ P, ET AL: Long-term intravenous epoprostenol infusion in primary pulmonary hypertension. Prognostic factors and survival. J Am Coll Cardiol 2002; 40: 780-788.

  19. RAYMOND RJ, HINDERLITER AL, WILLIS PW, RALPH D, CALDWELL EJ, WILLIAMS W, ET AL: Echocardiographic predictors of adverse outcome in primary pulmonary hypertension. J Am Coll Cardiol 2002; 39: 1214-1219.

  20. BUSTAMANTE-LABARTA M, PERRONE S, DE LA FUENTE RL, STUTZBACH P, DE LA HOZ RP, TORINO A, ET AL: Right atrial size and tricuspid regurgitation severity predict mortality or transplantation in primary pulmonary hypertension. J Am Soc Echocardiogr 2002; 15: 1160-1164.

  21. YEO TC, DUJARDIN KS, TEI C, MAHONEY DW, MCGOON MD, SEWARD JB: Value of a Doppler-derived index combining systolic and diastolic time intervals in predicting outcome in primary pulmonary hypertension. Am J Cardiol 1998; 81: 1157-1161.

  22. CURRIE PJ, SEWARD JB, CHAN KL, FYFE DA, HAGLER DJ, MAIR DD, ET AL: Continuous wave Doppler determinations of right ventricular pressure: a simultaneous Doppler-catheterization study of 127 patients. J Am Coll Cardiol 1985; 6: 750-756.

  23. BERGER B, HAIMOWITZ A, VAN TOSH A, BERDOFF RL, GOLDBERG E: Quantitative assessment of pulmonary hypertension in patients with tricuspid regurgitation using continuous wave Doppler ultrasound. J Am Coll Cardiol 1985; 6: 359-365.

  24. CHIN KM, KIM NHS, RUBIN LJ: The right ventricle in pulmonary hypertension. Coron Artery Dis 2005; 16: 13-18.

  25. HOPKINS WE, OCHOA LL, RICHARDSON GW, TRULOCK EP: Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome. J Heart Lung Transplant 1996; 15: 100-105.

  26. TAN LB, BAIN RJI, LITTLER WA: Assessing cardiac pumping capability by exercise testing and inotropic stimulation. Br Heart J 1989; 62: 20-25.

  27. LUPI HE, BIALOSTOZKY D, SOBRINO A: The role of isoproterenol in pulmonary artery hypertension of unknown etiology [Primary]. Short-and longterm evaluation. Chest 1981; 79: 292-296.

  28. LUPI HE, CAMACHO B, BIALOSTOZKY D, CONTRERAS M, MARTÍNEZ-GUERRA ML, BONETTI PF: Hipertensión arterial pulmonar de etiología desconocida. Estudio de la función cardiopulmonar. Arch Inst Cardiol Mex 1978; 48: 995-1110.

  29. LUPI HE, BIALOSTOZKY D: Respuesta cardiopulmonar al ejercicio en pacientes con hipertensión arterial pulmonar de etiología desconocida. Arch Inst Cardiol Mex 1979; 49: 969-983.

  30. LUPI HE, SANDOVAL J, SEOANE M, BIALOSTOZKY D, ATTIE F: The role of isoproterenol in the preoperative evaluation of high-pressure, high- resistance ventricular septal defect. Chest 1982; 81: 42-46.

  31. LUPI HE, SANDOVAL J, SEOANE M, BIALOSTOZKY D: The role of hydralazine therapy for pulmonary arterial hypertension of unknown cause. Circulation 1982; 65: 645-650.

  32. LUPI HE, SANDOVAL J, SEOANE M, BIALOSTOZKY D: Behavior of the pulmonary circulation in chronic obstructive pulmonary disease. Pathogenesis of pulmonary arterial hypertension at an altitude of 2,240 meters. Am Rev Respir Dis 1982; 126: 509-514.

  33. LUPI HE, SANDOVAL J, SEOANE M, BIALOSTOZKY D, VERDEJO J: La función ventricular derecha en la neumopatía obstructiva crónica con cardiopatía pulmonar, su estudio a la altura de la ciudad de México [2,240 metros]. Arch Inst Cardiol Mex 1981; 51: 535-540.

  34. LUPI HE, SEOANE M, SANDOVAL J, CASANOVA JM, BIALOSTOZKY D: Behavior of the pulmonary circulation in the grossly obese patient. Pathogenesis of pulmonary arterial hypertension at an altitude of 2,240 meters. Chest 1980; 78: 553-558.

  35. LUPI HE, SANDOVAL J, BIALOSTOZKY D, SEOANE M, MARTÍNEZ-GUERRA ML, FERNÁNDEZ BP, REYES P, BARRIOS R: Extrinsic allergic alveolitis caused by pigeon breeding at a high altitude [2,240 meters]. Hemodynamic behavior of pulmonary circulation. Am Rev Respir Dis 1981; 124: 602-607.

  36. DE MICHELLI A, VILLACIS E, GUZZY DMP, RUBIO VA: Observaciones sobre los valores hemodinámicos y respiratorios obtenidos en sujetos normales. Arch Inst Cardiol Mex 1960; 30: 507-520.

  37. ROZKOVEC A, MONTANES P, OAKLEY CM: Factors that influence the outcome of primary pulmonary hypertension. Br Heart J 1986; 55: 449-458.

  38. GLANVILLE AR, BURKE CM, THEODORE J, ROBIN ED: Primary pulmonary hypertension. Length of survival in patients referred for heart-lung transplantation. Chest 1987; 91: 675-681.

  39. ABRAHAM WT, RAYNOLDS MV, BADESCH DB, WYNNE KM, GROVES BM, RODEN RL, ROBERTSON AD, LOWES BD, ZISMAN LS, VOELKEL NF, BRISTOW MR, PERRYMAN MB: Angiotensin-converting enzyme DD genotype in patients with primary pulmonary hypertension: increased frequency and association with preserved hemodynamics. J Renin Angiotensin Syst 2003; 4: 27-30.

  40. ABRAHAM WT, RAYNOLDS MV, GOTTSCHALL B, BADESCH DB, WYNNE KM, GROVES BM, ET AL: Importance of angiotensin-converting enzyme in pulmonary hypertension. Cardiology 1995; 86 [Suppl 1]: 9-15.

  41. MONTALESCOT G, DROBINSKI G, MEURIN P, MACLOUF J, SOTIROV I, PHILIPPE, ET AL: Effects of prostacyclin on the pulmonary vascular tone and cardiac contractility of patients with pulmonary hypertension secondary to end-stage heart failure. Am J Cardiol 1998; 82: 749-755.

  42. VAN SUYLEN RJ, WOUTERS EF, PENNINGS HJ, CHERIEX EC, VAN POL PE, AMBERGEN AW, ET AL: The DD genotype of the angiotensin converting enzyme gene is negatively associated with right ventricular hypertrophy in male patients with chronic obstructive lung disease. Am J Respir Crit Care Med 1999; 159: 1791-1795.

  43. KANAZAWA H, OKAMOTO T, HIRATA K, YOSHIKAWA J: Deletion polymorphism in the angiotensin converting enzyme gene are associated with pulmonary hypertension evoked by exercise challenge in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 162: 1235-1238.

  44. SANDOVAL J, ROTHMAN A, PULIDO T: Atrial septostomy for pulmonary hypertension. Clin Chest Med 2001; 22: 547-560.




2020     |     www.medigraphic.com